Table III.
Univariate analysis of acute and chronic GVHD at day 30 and day 100 (all patients).
| N | Acute GVHD II–IV, day30
|
Acute GVHD II–IV, day 100
|
|||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | ||
| Group | |||||||
| PTCy group | 41 | NE | 0.01 | 0.97 | 0.5–1.8 | 0.9 | |
| Conventional group | 72 | Ref. | |||||
| Gender mismatch | |||||||
| Female-Male | 22 | 1.7 | 0.4–6.3 | 0.45 | 1.3 | 0.6–2.6 | 0.5 |
| Others | 84 | Ref. | Ref. | ||||
| Age, years | |||||||
| ≤40 | 26 | Ref. | Ref. | ||||
| 41–50 | 19 | 1.4 | 0.2–10.2 | 0.7 | 1.3 | 0.5–3.2 | 0.5 |
| 51–55 | 17 | 0.7 | 0.1–8.1 | 0.8 | 0.7 | 0.2–2.2 | 0.6 |
| 56–60 | 17 | 1.5 | 0.2–10 | 0.7 | 1.5 | 0.6–3.7 | 0.3 |
| >60 | 27 | 1.4 | 0.2–8.4 | 0.7 | 0.7 | 0.3–1.8 | 0.5 |
| Graft source | |||||||
| Bone marrow | 74 | Ref. | Ref. | ||||
| Peripheral blood | 32 | 1.5 | 0.4–5.4 | 0.5 | 0.7 | 0.3–1.5 | 0.4 |
| Diagnosis | |||||||
| Lymphoid malignancies | 49 | 1.8 | 0.5–6.3 | 0.4 | 1.4 | 0.8–2.6 | 0.3 |
| Myeloid malignancies | 57 | Ref. | Ref. | ||||
| Disease Risk Index | |||||||
| Very High | 14 | Ref. | Ref. | ||||
| High | 31 | 0.5 | 0.1–3.2 | 0.4 | 1.3 | 0.5–3.6 | 0.6 |
| Intermediate | 30 | 0.7 | 0.1–4.1 | 0.7 | 1.2 | 0.4–3.3 | 0.8 |
| Low | 27 | 0.8 | 0.1–4.4 | 0.8 | 0.9 | 0.3–2.7 | 0.8 |
| Missing | 4 | NE | 0.7 | 0.1–6.4 | 0.7 | ||
| Conditioning regimen | |||||||
| Myeloablative | 55 | Ref. | Ref. | ||||
| Reduced-intensity | 51 | 1.6 | 0.5–5.8 | 0.4 | 1.2 | 0.6–2.1 | 0.6 |
| Year of transplantation | |||||||
| 2009 | 16 | Ref. | Ref. | ||||
| 2010 | 29 | 0.3 | 0.06–2.0 | 0.2 | 0.7 | 0.2–2.0 | 0.5 |
| 2011 | 30 | 0.7 | 0.1–2.9 | 0.6 | 1.05 | 0.4–2.9 | 0.9 |
| 2012 | 23 | NE | 0.9 | 0.3–2.7 | 0.9 | ||
| 2013 | 8 | 0.6 | 0.1–5.9 | 0.7 | 2 | 0.6–7.1 | 0.3 |
| 2009 vs. >2009 | 2.6 | 0.7–10 | 0.2 | ||||
CI, Confidence Interval; HR, Hazard Ratio; NE, Not evaluable; PTCy, Post-transplant cyclophosphamide, GVHD, graft-versus-host disease; Ref., reference.